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The [4π+2π] cycloaddition of non-classical heterocyclic-fused-[c]thiazoles was explored allowing the 
synthesis of a range of new nitrogen-bridged bi-, tri- and tetracyclic heterocyclic compounds namely, 
pyrazolo[1,5-a]pyridines, thiazolo[2,3,4-cd]pyrrolizines and indolizines. For the first time, one non-
classical pyrrolo[1,2-c]thiazole was isolated and its structure determined by X-ray crystallography. 
 
1. Introduction 
 
Heteropentalene mesomeric betaines are bicyclic 10π-electron heterocycles isoconjugate with the 
pentalenyl dianion which cannot be represented by classic covalent Kekulé structures. They can only be 
represented by dipolar structures or by structures involving tetravalent sulphur atoms. Their interesting 
electronic structure makes them of interest from both theoretical and synthetic point of view. These non-
classical heteropentalenes are versatile substrates in cycloaddition reactions for the construction of a 
variety of fused heterocycles.
1
 
The non-classical heteropentalenes 2, containing a tetravalent sulphur atom, can be generated in situ 
via Pummerer-type dehydration of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 1a and 2-oxo-1H,3H-
pyrazolo[1,5-c]thiazole 1b, respectively (Scheme 1). These transient heterocyclic-fused-[c]thiazole 
systems 2 participate in [4π+2π] cycloadditions to give fused heterocycles.2,3 Heteropentalene 2a reacts as 
thiocarbonyl ylide in the reaction with N-substituted maleimides, whereas with acetylene dicarboxylate 
intermediate 2a acts as an azomethine ylide. Heteropentalene 2b reacts with both types of dipolarophiles, 
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2 
giving products resulting from the addition across the thiocarbonyl ylide moiety. 
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Scheme 1. [4π+2π] cycloadditions of non-classical heterocyclic-fused-[c]thiazoles 2. 
 
This chemistry allows the synthesis of interesting nitrogen-bridged bicyclic and tricyclic heterocyclic 
compounds namely, pyrazolo[1,5-a]pyridines, thiazolo[2,3,4-cd]pyrrolizines and indolizines. In fact, 
indolizine is an important structural unit commonly found in naturally occurring alkaloids and 
biologically active molecules, thus representing an important class of heterocycles in drug discovery. For 
instance, substituted indolizines have shown antioxidant
4
 and antimycobacterial properties,
5
 while some 
derivatives are slow-channel calcium antagonists
6
 and others show inhibitory activity of secretory 
phospholipases A2,
7
 phosphatase
8
 and 15-lipoxygenase.
9
 On the other hand, indolizine-glyoxylamides 
showed cytotoxicity against multidrug resistant cancer cell lines.
10
 Pyrazolo[1,5-a]pyridines represent 
another important class of N-bridged heterocycles with recognized biological activity. Compounds 
incorporating a pyrazolo[1,5-a]pyridine core are highly selective dopamine D3 and D4 receptor agonists 
and antagonists used for the treatment of neurophathological disorders such as schizophrenia and 
Parkinson’s disease.11 Some derivatives were found to be selective adenosine A1 receptor antagonists with 
potent diuretic
12
 and herpetic activity.
13
 More recently a 2,3-substituted pyrazolo[1,5-a]pyridine was 
identified as a promising p38 kinase inhibitor.
14
 
In this context, the chemistry of non-classical heterocyclic-fused-[c]thiazoles was further explored 
aiming to access a range of new nitrogen-bridged bicyclic and tricyclic heterocyclic compounds. 
 
 
2. Results and Discussion 
 
Initially, we looked again into cycloadditions of heteropentalene 2a with N-phenylmaleimide (NPM) 
and dimethyl acetylene dicarboxylate (DMAD) reported by Kane and Storr (Table 1).
2,3
 Pummerer-type 
dehydration of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 1a in boiling acetic anhydride in the presence of 
NPM gave a mixture of the exo- and endo-cycloadducts via [4π+2π] cycloaddition across the thiocarbonyl 
ylide portion of heteropentalene 2a as previously described
2,3
 (Table 1). Carrying out the reaction for 4 h 
the exo-cycloadduct 3a was isolated in 54% yield as the major product together with the synthesis of the 
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3 
endo-cycloadduct 3b in 8% yield (Table 1, Entry 1). Longer reaction time led to compound 3a in low 
yield, indicating lack of stability of the cycloadducts to these reaction conditions (Table 1, Entry 2).  
Sealed tube thermolysis at 140 ºC for 4 h gave a good overall yield, the exo-cycloadduct 3a being again 
the major product (Table 1, Entry 3). It was demonstrated that heteropentalene 2a can also be generated 
under microwave irradiation (MW). The same pattern of reactivity was observed in the cycloaddition of 
2a with NPM carrying out the microwave irradiation with the temperature set to 140 ºC for 20 minutes, 
giving exo- and endo-cycloadducts 3 in 83% overall yield (Table 1, Entry 4). 
 
Table 1 
Cycloaddition of heteropentalene 2a generated from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 1a. 
 
N
OS
Me
CO2Me
CO2Me
1a
N
Me
CO2Me
CO2Me
N
O
O
S
N
Me
CO2Me
CO2Me
N
O
O
S
Ac2O, NPM
3a 3b
N
S
CO2Me
CO2Me
CO2MeMeO2C
Me
4
PhPh
Ac2O
DMAD
 
Entry Dipolarophile Reaction Conditions Products (Yield) 
1 NPM Reflux, 4 h   3a (54%) 3b (8%) 
2 NPM Reflux, 7 h  3a (16%) --- 
3 NPM Sealed tube, 140 ºC, 4 h 3a (58%) 3b (14%) 
4 NPM MW, 180 ºC, 20 min 3a (73%) 3b (10%) 
5 DMAD Reflux, 4 h  4 (51%) 
6 DMAD Sealed tube, 140 ºC, 4 h 4 (35%) 
7 DMAD MW, 180 ºC, 20 min 4 (15%) 
 
The reaction of 1a and DMAD in boiling acetic anhydride afforded the 1:1 adduct thiazolo[2,3,4-
cd]pyrrolizine 4 in 51% yield via cycloaddition across the azomethine ylide portion of the non-classical 
heterocyclic-fused-[c]thiazole 2a (Table 1, Entry 5). Under these reaction conditions a complex mixture 
was obtained but crystallisation from methanol gave compound 4 in pure form, as described in the 
literature.
2,3
 Carrying out the thermolysis at 140 ºC in a sealed tube for 4 h the tricyclic heterocyclic 
compound 4 was obtained in moderate yield (35%) whereas under microwave irradiation at 180 ºC for 20 
minutes the target molecule 4 could only be isolated in 15% yield (Table 1, Entries 6 and 7). Thus, 
conventional thermolysis are the best reaction conditions for the synthesis of heterocycle 4. 
Subsequently, dehydration of 2-oxo-pyrazolo[1,5-c]thiazole 1b in the presence of NPM and DMAD 
was explored (Table 2). In both cases exclusive formation of cycloadducts resulting from the addition 
across the thiocarbonyl ylide moiety of the non-classical fused-[c]thiazole 2b was observed, as described 
in the literature.
2,3
 The cycloaddition of 2b with N-phenylmaleimide carried out in boiling acetic 
anhydride for 4 h gave exo-adduct 5 selectively in 42% yield (Table 2, Entry 1). The yield for the 
synthesis of compound 5 could be improved to 76% by increasing the reaction time to 7 h (Table 2, Entry 
2). The same compound could also be obtained in good yield under sealed tube thermolysis (Table 2, 
Entries 3 and 4). The microwave induced reaction of heteropentalene 2b with NPM gave compound 5 in 
54% yield (Table 2, Entry 5). 
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Table 2 
Cycloaddition of heteropentalene 2b generated from 2-oxo-1H,3H-pyrazolo[1,5-c]thiazole 1b. 
 
N
N
OS CO2Me
CO2Me
1b
N N
CO2Me
CO2Me
N
O
O
S
Ac2O
5
N
N
CO2Me
CO2Me
MeO2C
MeO2C
6
Ac2O
NPM
DMAD
Ph
 
Entry Dipolarophile Reaction Conditions Products (Yield) 
1 NPM Reflux, 4 h   5 (42%) 
2 NPM Reflux, 7 h  5 (76%) 
3 NPM Sealed tube, 140 ºC, 4 h 5 (65%) 
4 NPM Sealed tube, 140 ºC, 7 h 5 (71%) 
5 NPM MW, 180 ºC, 15 min 5 (54%) 
6 DMAD Reflux, 4 h  6 (26%) 
7 DMAD Reflux, 7 h  6 (45%) 
8 DMAD Sealed tube, 140 ºC, 4 h 6 (45%) 
9 DMAD MW, 160 ºC, 10 min 6 (30%) 
10 DMAD MW, 180 ºC, 15 min 6 (53%) 
 
The non-classical thiazole 2b reacts with DMAD giving pyrazolo[1,5-a]pyridine 6 resulting from the 
initial cycloaddition across the thiocarbonyl ylide portion of 2b followed by spontaneous loss of sulphur. 
Carrying out the reaction in boiling acetic anhydride for 4 h compound 6 was obtained in only 26% yield 
but with a longer reaction time the yield could be improved to 45% (Table 2, Entries 6 and 7). The same 
yield was obtained carrying out the sealed tube thermolysis at 140 ºC for 4 h (Table 2, Entry 8). The 
dehydration of 2-oxo-pyrazolo[1,5-c]thiazole 1b and the subsequent cycloaddition with DMAD was also 
achieved under microwave irradiation (Table 2, Entries 9 and 10). The best reaction conditions, 
microwave irradiation at 180 ºC for 15 minutes, afforded compound 6 in 53% yield. 
Semi-empirical calculations reported by Storr et al. indicated that the cycloaddition of non-classical 
thiazoles 2 is dipole-HOMO controlled.
3
 On the other hand the coefficients in the HOMO suggest that the 
addition across both thiocarbonyl ylide and azomethine or azomethine imine ylide portion of 2a and 2b, 
respectively, would be possible. However, exclusive formation of pyrazolo[1,5-a]pyridine adducts from 
2b in contrast with the synthesis of both types of adducts from 2a can be explained considering the type 
of bonds being formed in each case. As mentioned by the authors, the calculation did not take into 
account this fact. In the case of 2a both types of additions lead to two new carbon-carbon bonds whereas 
in the case of 2b addition across the thiocarbonyl ylide moiety also leads to two new carbon-carbon bonds 
but the addition across the azomethine imine portion would lead to the formation of a carbon-carbon bond 
and to a less favourable carbon-nitrogen bond. 
The work was extended to the synthesis and reactivity of new 3-benzyl and 2-oxo-3-methyl-1H,3H-
pyrrolo[1,2-c]thiazoles 8a and 8b in order to evaluate the scope of this approach to nitrogen-bridged 
heterocycles (Scheme 2, Tables 3 and 4). 1H,3H-Pyrrolo[1,2-c]thiazole 7a and 7b were prepared by a 
known procedure
15
 and converted into the corresponding sulfoxides 8 by oxidation with MCPBA 
(Scheme 2).  
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N
S
Me
CO2Me
CO2Me
7a  R = Bn
7b  R = Me
R
N
OS
Me
CO2Me
CO2Me
79%
57%
R
MCPBA
8a  R = Bn
8b  R = Me  
Scheme 2. Synthesis of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 8. 
 
Interestingly, the oxidation of chiral 3-benzyl-1H,3H-pyrrolo[1,2-c]thiazole 7a gave the 
corresponding sulfoxide 8a as a 9:1 mixture of diastereoisomers which could be separated by flash 
chromatography to give the optically pure sulfoxides. The major isomer was isolated in 76% yield and the 
minor isomer was obtained in 3% yield. Thus, using an achiral oxidant a diastereoselective reaction was 
achieved, the stereochemistry of the sulfoxide being induced by the proximity of the chiral center at the α-
position of 1H,3H-pyrrolo[1,2-c]thiazole 7a. Chiral sulfoxides are valuable for asymmetric synthesis due 
to the high asymmetric induction that can be exerted by the chiral sulfinyl group, making them interesting 
target molecules.
16
 
Pummerer-type dehydration of 2-oxo-3-benzyl-1H,3H-pyrrolo[1,2-c]thiazole 8a in the presence of N-
substituted maleimides was studied (Table 3). Under conventional heating for 4 h the cycloaddition 
reaction with N-phenylmaleimide gave a mixture of the exo- and endo-cycloadducts 9a and 10a in 22% 
and 20% yield, respectively (Table 3, Entry 1). Interestingly, from this reaction the non-classical thiazole 
11 resulting from sulfoxide 8a dehydration, was also isolated. The structure of heterocycle 11 was 
established by X-ray crystallography (Figure 1). This compound crystallized, in the monohydrated form, 
as yellow plates in the monoclinic system within Cc space group, showing a planar heterocyclic 
backbone. All distances and angles are within the expected values for similar compounds,
17
 the benzyl 
substituent making an angle of 33.7º with the pyrrolo[1,2-c]thiazole. The carboxylate substituents on 
consecutive carbons of the pyrrole fragment, make an angle of 47.0º due to the high steric hindrance 
introduced. 
 
Table 3 
Generation and cycloaddition of heteropentalene 11. 
 
N
Me
CO2Me
CO2Me
N
O
O
S
N
Me
CO2Me
CO2Me
N
O
O
S
9a R = Ph
9b R = Me
10a R = Ph
10b R = Me
Ac2O
N
OS
Me
CO2Me
CO2Me
8a
Bn
Bn Bn
N
S
Me
CO2Me
CO2Me
11
Bn
Ac2O
NPM or 
NMM
11RR
 
Entry Dipolarophile Reaction 
Conditions 
Products (Yield) 
1 NPM Reflux, 4 h   9a (22%) 10a (20%) 11 (23%) 
2 NPM MW, 160 ºC 9a (10%) 10a (23%) 11 (36%) 
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6 
20 min 
3 NMM Reflux, 4 h  9b (10%) 10b (39%) 11 (21%) 
4 NMM Sealed tube 
140 ºC, 4 h 
--- 10b (10%) 11 (16%) 
5 NMM MW, 160 ºC 
20 min 
9b (6%) 10b (8%) 11 (17%) 
6 ---- Reflux, 4 h  11 (50%) 
7 ---- MW, 160 ºC 
25 min 
11 (33%) 
 
 
 
Figure 1. ORTEP-3 diagram of compound 11, using 50% probability level ellipsoids. Hydrogen atoms have been 
omitted for clarity. 
 
The exo/endo assignments of cycloadducts 9a and 10a were based on previously described 
1
H NMR 
data of similar derivatives, characterized by a larger deshielding effect of the sulphur bridge on the imide 
α-protons of the endo-cycloadduct.3,18 The structural assignment of compound 10a was also supported by 
two-dimensional HSQC and NOESY spectra (400 MHz). In the NOESY spectrum sulphur bridge proton 
H-9 (5.28 ppm) shows connectivity with imide α-proton H-9a (3.98 ppm) and aliphatic benzyl protons 
(3.78 and 4.38 ppm) are correlated with imide α- proton H-3a (3.92 ppm). 
 Under microwave irradiation at 160 ºC for 20 minutes compounds 9a, 10a and 11 were obtained, the 
heteropentalene 11 being the major product (Table 3, Entry 2). The reaction of 2-oxo-3-benzyl-1H,3H-
pyrrolo[1,2-c]thiazole 8a with N-methylmaleimide in boiling acetic anhydride for 4 h gave the expected 
1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizines 9b and 10b 
together with the formation of heteropentalene 11 in 70% overall yield (Table 3, Entry 3). From the 
sealed tube thermolysis only endo-cycloadduct 10b and compound 11 could be isolated in 10% and 16% 
yield, respectively (Table 3, Entry 4). The microwave induced reaction of sulfoxide 8a in the presence of 
NMM gave compounds 9b, 10b and 11 in low overall yield (Table 3, Entry 5). 
 In the absence of a dipolarophile the dehydration of 2-oxo-3-benzyl-1H,3H-pyrrolo[1,2-c]thiazole 8a in 
boiling acetic anhydride for 4 h gave the non-classical heterocyclic-fused-[c]thiazole 11 in 50% yield 
whereas from the microwave induced dehydration compound 11 was isolated in lower yield (Table 3, 
Entries 6 and 7). However, attempts to carry out the reaction of non-classical heteropentalene 11 with 
NPM under conventional heating or under microwave irradiation only led to complex mixtures. 
 Although these new disubstituted heteropentalenes showed the expected reactivity for the [4π+2π] 
cycloaddition with maleimides, no reaction was observed with acetylene dicarboxylate. 
 The chemical behaviour of 2-oxo-3-methyl-1H,3H-pyrrolo[1,2-c]thiazole 8b under thermolysis in 
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7 
acetic anhydride in the presence of dipolarophiles was similar to the one observed for sulfoxide 8a. In 
fact, [4π+2π] cycloadducts were obtained from the reaction with maleimides but no reaction was 
observed with acetylene dicarboxylate (Table 4). However, in this case the heteropentalene generated in 
situ from compound 8b could not be isolated. The reaction of sulfoxide 8b with NPM in boiling acetic 
anhydride for 4 h gave exo-cycloadduct 12a and endo-cycloadduct 13a in 39% and 15% yield, 
respectively (Table 4, Entry 1). Carrying out the reaction in a sealed tube at 140 ºC for 4 h compound 12a 
was obtained in 36% yield and only traces of compound 13a could be detected (Table 4, Entry 2). Under 
microwave irradiation compound 12a was isolated in 20% yield (Table 4, Entry 3). The reaction of 
sulfoxide 8a with N-methylmaleimide in boiling acetic anhydride or under sealed tube thermolysis gave 
the expected endo- and exo-cycloadducts 12b and 13b (Table 4, Entries 4 and 5). 
 
Table 4 
Cycloaddition of the heteropentalene generated from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 8b. 
 
N
Me
CO2Me
CO2Me
N
O
O
S
N
Me
CO2Me
CO2Me
N
O
O
S
12a R = Ph
12b R = Me
13a R = Ph
13b R = Me
Ac2O
N
OS
Me
CO2Me
CO2Me
8bMe
Me Me
NPM or 
NMM
R R
 
Entry Dipolarophile Reaction Conditions Products (Yield) 
1 NPM Reflux, 4 h   12a (39%) 13a (15%) 
2 NPM Sealed tube, 140 ºC, 4 h 12a (36%) 13a  trace 
3 NPM MW, 140 ºC, 20 min 12a (20%) 13a  trace 
4 NMM Reflux, 4 h  12b (9%) 13b (23%) 
5 NMM Sealed tube, 140 ºC, 4 h 12b (20%) 13b (19%) 
 
 The mixture of exo- and endo-cycloadducts 9a/10a and 12/13 underwent elimination of hydrogen 
sulfide on treatment with sodium methoxide or potassium tert-butoxide to afford indolizines 14 (Scheme 
3). Attempts to promote the elimination of hydrogen sulfide with sodium methoxide from adducts 9b/10b 
was not successful and led only to the recovery of the staring material. On the other hand, reaction with 
potassium tert-butoxide led to a complex mixture. 
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49 
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51 
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55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
9a/10a    R1 = Ph; R2 = Bn
12a/13a  R1 = Ph; R2 = Me
12b/13b  R1 = R2 = Me
N
Me
CO2Me
CO2Me
N
O
O
S
R2
N
Me
CO2Me
CO2Me
N
O
O R2
14a  R1 = Ph; R2 = Bn
14b  R1 = Ph; R2 = Me  
14c  R1 = R2 = Me
NaOMe or t-BuOK
R1
R1
38%
87%
50%  
Scheme 3. Desulfirization of 4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizines. 
 
The heteropentalenes derived from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazoles studied so far were 5-
substituted heteropentalene 2a or 3,5-substituted heteropentalenes (compound 11 and the heteropentalene 
derived from 8b). Only the non-classical thiazole 2a reacted as thiocarbonyl ylide in the reaction with N-
substituted maleimides and as an azomethine ylide with acetylene dicarboxylate. Therefore, considering 
that steric effects may play a role in the observed reactivity, we decided to prepare and explore the 
reactivity of new 3,5-unsubstituted heteropentalenes. 
3,5-Unsubstituted-1H,3H-pyrrolo[1,2-c]thiazole sulfoxide 18 was prepared as outlined in Scheme 4. 
Formylation of thiazolidine 15 in high yield was achieved by the reaction with formic acid and acetic 
anhydride following a known procedure.
19 
Treatment of the N-formylthiazolidine 16 with triethylamine 
and tosyl chloride in the presence of dimethyl acetylenedicarboxylate afforded pyrrolo[1,2-c]thiazole 17 
in 64% yield. The oxidation of 17 with MCPBA afforded sulfoxide 18 in 52% yield. 
 
S NH
CO2H
S N
CO2H
NEt3, TsCl
N
S CO2Me
CO2Me
N
OS CO2Me
CO2Me
MCPBA
16  99%
17   64% 18   52%
15
DMAD
CHO
HCO2H
Ac2O
 
Scheme 4. Synthesis of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 18. 
 
Dehydration of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 18 led to the target 3,5-unsubstituted 
heteropentalene which was trapped with maleimides leading to products resulting from both additions 
across the thiocarbonyl ylide (compounds 19 and 20) and azomethine ylide moieties (compound 21) 
(Table 5). Carrying out the reaction of sulfoxide 18 in boiling acetic anhydride in the presence of NPM 
for 4 h cycloadducts 19a (33%) and 21a (18%) were obtained (Table 5, Entry 1) whereas the sealed tube 
thermolysis gave compounds 19a, 20a and 21a in 47% overall yield (Table 5, Entry 2). The microwave 
induced reaction allowed the synthesis of the products resulting from the cycloaddition across the 
thiocarbonyl ylide portion of the in situ generated heteropentalene, the exo-cycloadduct 19a in 55% yield 
and the endo-cycloadduct 20a in 13% yield (Table 5, Entry 3). The dehydration of 2-oxo-1H,3H-
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9 
pyrrolo[1,2-c]thiazole 18 was also carried out in the pesence of NMM under different reaction conditions 
(Table 5, Entries 4-6). In all cases 19b, 20b and 21b were obtained. Thus, for the first time a pyrrolo[1,2-
c]thiazole heteropentalene reacted with N-substituted maleimides not only as a thiocarbonyl ylide but also 
as an azomethine ylide. 
 
Table 5 
Cycloaddition of the heteropentalene generated from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 18. 
 
N
CO2Me
CO2Me
N
O
O
S
Ac2O
N
OS CO2Me
CO2Me
NPM or NMM
N
S
N
CO2Me
OO
H
CO2Me
19a R = Ph
19b R = Me
18
21a  R = Ph
21b  R = Me
N
CO2Me
CO2Me
N
O
O
S
20a  R = Ph
20b  R = Me
R
R
R  
Entry Dipolarophile Reaction 
Conditions 
Products (Yield) 
1 NPM Reflux, 4 h   19a (33%) --- 21a (18%) 
2 NPM Sealed tube 
140 ºC, 4 h 
19a (28%) 20a (7%) 21a (12%) 
3 NPM MW, 180 ºC 
20 min 
19a (55%) 20a (13%) --- 
4 NMM Reflux, 4 h  19b (20%) 20b (9%) 21b (27%) 
5 NMM Sealed tube 
140 ºC, 4 h 
19b (19%) 20b (2%) 21b (16%) 
6 NMM MW, 180 ºC 
 20 min 
19b (19%) 20b (8%) 21b (26%) 
 
The mixture of exo- and endo-cycloadducts 19/20 underwent elimination of hydrogen sulfide on 
treatment with potassium tert-butoxide to afford indolizines 22. 
 
N
CO2Me
CO2Me
N
O
O
22a  R = Ph    35%
22b  R = Me   38%
R
 
 
The work was extended to a new non-classical thiazole derived from 3,5-unsubstituted-1H,3H-
pyrrolo[1,2-c]thiazole sulfoxide 24 (Table 6). Pyrrolo[1,2-c]thiazole 23 bearing only one trifluoromethyl 
group at C-7 was converted into the corresponding sulfoxide 24 by catalytic oxidation. By adjustment of 
an experimental procedure described in the literature for the synthesis of 2,2-dioxo-7-trifluoromethyl-
1H,3H-pyrrolo[1,2-c]thiazole
20
 a 92:8 mixture of sulfoxide 24 and the corresponding sulfone was 
obtained as a solid (using 2.4 equiv. of hydrogen peroxide). The solid was washed with diethyl ether 
giving sulfoxide 24 in pure form in 90% yield, without the need for further purification.  
Dehydration of 24 in the presence of NPM led to a mixture of the exo- and endo-cycloadducts 25 (R = 
Ph). Sigmatropic H shift of these cycloadducts afforded the final products 26a and 27a in moderate yield 
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10 
either in boiling acetic anhydride or under sealed tube thermolysis (Table 6, Entries 1-3). However, under 
microwave irradiation only traces of these products could be detected (Table 6, Entry 4). The structure of 
heterocycle 27a was determined by X-ray crystallography (Figure 2). This compound crystallized as 
colourless prisms in the triclinic system within P-1 space group, as a racemic mixture. All distances and 
angles are within the expected values for similar compounds.
17
 The compound displays an endo 
configuration, which is attested not only by the torsion angles around C4a-C4b and C7a-C7b (see 
Supplementary Information), but also from the angles between planes [C4b-C5-N6-C7-C7a] and [C4a-
C4b-C7b-C7a-N8]; [C4b-C5-N6-C7-C7a] and [C2a-C3-C4-C4a-N8], and [C4a-C4b-C7b- C7a-N8] and 
[C2a-C3-C4-C4a-N8], respectively 64.5, 24.4 and 87.8º. The thiazolemoiety adopts an evelope 
conformation characterized by a value of 31.4º for the hinge angle that represents the bending at a line 
defined by atoms C2 and C7b. 
 
 
 
Figure 2. ORTEP-3 diagram of 5,7(4bH,6H)-dioxo-6-phenyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-
pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine 27a, using 50% probability level ellipsoids. Hydrogen atoms have been 
omitted for clarity. 
 
Table 6 
Cycloaddition of the heteropentalene generated from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 24. 
 
N
S
N
CF3
OO
N
S
N
CF3
OO
N
S
CF3
23
N
OS
CF3
24  90%
Ac2O
26a  R = Ph
27a  R = Ph
27b  R = Me
H H
NPM
or 
NMM
N
S
N
CF3
OO
25
H2O2
Na2WO4
R
R R  
 
Entry Dipolarophile Reaction Conditions Products (Yield) 
1 NPM Reflux, 4 h   26a (8%) 27a (13%) 
2 NPM Reflux, 7 h  26a (11%) 27a (30%) 
3 NPM Sealed tube, 140 ºC, 7 h 26a (10%) 27a (26%) 
4 NPM MW, 140 ºC, 20 min 26a trace 27a trace 
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5 NMM Reflux, 7 h --- 27b (50%) 
6 NMM Sealed tube, 140 ºC, 7 h --- 27b (63%) 
 
The dehydration of sulfoxide 24 in the presence of N-methylmeleimide was also explored, which led 
to the exclusive formation of the endo-cycloadduct 27b (Scheme 10). Carrying out the reaction in boiling 
acetic anhydride for 7 h compound 27b was obtained in 50% yield (Table 6, Entry 5). The sealed tube 
thermolysis allowed the isolation of the same product in 60 % yield (Table 6, Entry 6). 
We could conclude that the heteropentalene derived from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole 24 
participates in [4π+2π] cycloadditions with N-substituted maleimides, but only as an azomethine ylide. 
Thus, steric and electronic factors must be considered in order to rationalize the observed selectivity. 
 
 
3. Conclusions 
 
The [4π+2π] cycloaddition of non-classical heterocyclic-fused-[c]thiazoles generated by dehydration 
of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazoles and 2-oxo-1H,3H-pyrazolo[1,5-c]thiazoles has been investigated 
giving access to new nitrogen-bridged bi-, tri- and tetracyclic heterocyclic compounds. 
The reported results allowed for the definition of a reactivity pattern of this type of heteropentalenes 
towards N-substituted maleimides. The cycloaddition of the heteropentalene formed by dehydration of 2-
oxo-1H,3H-pyrazolo[1,5-c]thiazole-6,7-dicarboxylate leads to products resulting from the exclusive 
addition across the thiocarbonyl ylide moiety. 5-Substituted and 3,5-substituted heteropentalenes derived 
from 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylates also react with N-substituted maleimides as 
thiocarbonyl ylide exclusively whereas the cycloaddition of the 3,5-unsubstituted derivative led to 
cycloadducts resulting from both the addition across the thiocarbonyl and azomethine ylide moieties. 
Interestingly, the non-classical heterocyclic-fused-[c]thiazole formed by dehydration of the 2-oxo-1H,3H-
pyrrolo[1,2-c]thiazole bearing only one trifluoromethyl group at C-7 reacted with N-substituted 
maleimides selectively as an azomethine ylide. Therefore, both steric and electronic factors must be 
considered in order to rationalize the observed selectivity. 
For the first time, one non-classical pyrrolo[1,2-c]thiazole was isolated and its stucture determined by 
X-ray crystallography. 
 
 
4. Experimental  
 
4.1. General Methods. 
 
1
H NMR spectra were recorded on an instrument operating at 300 or at 400 MHz. 
13
C NMR spectra 
were recorded on an instrument operating at 100 MHz. Chemical shifts are expressed in parts per million 
related to internal TMS, and coupling constants (J) are in Hz. IR spectra were recorded on a Nicolet 6700 
FTIR spectrometer. Mass spectra were recorded under electron impact (EI) or electrospray ionization 
(ESI). HRMS spectra were recorded on a Finnigan MAT95 S instrument. Melting points were determined 
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12 
in open glass capillary with an Electrothermal melting point apparatus and are uncorrected. Flash column 
chromatography was performed with Merck 9385 silica as the stationary phase. Microwave reactions 
were carried out in a microwave reactor CEM Focused Synthesis System, Discover S-Class. 
1,3-Thiazolidine-4-carboxylic acid 15,
3 
1H,3H-pyrrolo[1,2-c]thiazoles 7
19
 and 23
20
, 2-oxo-1H,3H-
pyrrolo[1,2-c]thiazole 1a
3 
and 2-oxo-1H,3H-pyrazolo[1,5-c]thiazole 1b
3
 were prepared as described in the 
literature. 
 
4.2. Specific chemical procedures. 
 
4.2.1. N-Formylthiazolidine-4-carboxylic acid (16). 1,3-Thiazolidine-4-carboxylic acid 15 (6.85 g, 51.5 
mmol) was added to formic acid (53.0 mL), the temperature of the reaction medium being kept below 25 
ºC. Acetic anhydride (35.0 mL) was added dropwise to the solution while maintaining the temperature 
between 10 and 18 ºC. After stirring for 20 h at a temperature of the order of 20 ºC, the solvent was 
evaporated off. The compound was obtained as a colourless oil (99%). IR (film) 2934, 1736, 1665, 1384, 
1216 cm
-1
. 
1
H NMR (400 MHz, CDCl3) Major isomer: δ 3.29-3.38 (m, 2H), 4.63 (d, J = 8.8 Hz, 1H), 
4.70 (d, J = 8.8 Hz, 1H), 5.09 (approx. t, J = 5.6 and 6.0 Hz, 1H), 7.64 (bs, 1H, OH), 8.35 (s, 1H, CHO); 
Minor isomer: δ 3.29-3.38 (m, 1H), 3.45 (dd, J = 1.6 and 11.6 Hz, 1H), 4.45 (d, J = 9.6 Hz, 1H), 4.76 (d, 
J = 9.6 Hz, 1H), 4.83-4.84 (m, 1H), 7.64 (bs, 1H, OH), 8.34 (s, 1H, CHO). MS (EI) m/z 161 (M
+
, 17%), 
116 (26), 89 (100). HRMS (EI-TOF) m/z 161.0151 (M
+
, C5H7NO3S requires161.0147). 
 
4.2.2. Dimethyl 1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (17). Triethylamine (5.2 mL, 37.7 
mmol) was added to a suspension of N-formylthiazolidine-4-carboxylic acid 16 (5.52 g, 34.3 mmol) in 
dry dichloromethane (15.0 mL).  This solution was added dropwise to a mixture of tosyl chloride (7.34 g, 
37.7 mmol) in dichloromethane (15.0 mL) at 40 ºC.  Dimethyl acetylene dicarboxylate (4.7 mL, 38.4 
mmol) was then added quickly followed by triethylamine (10.4 mL, 75.4 mmol).  The reaction mixture 
was maintained refluxing for 3 h.  After cooling to room temperature water was added and the organic 
layer was separated. The aqueous phase was extracted with dichloromethane and the organic extracts are 
combined, dried over anhydrous sodium sulfate and the solvent evaporated off.  Purification by flash 
chromatography [hexane- ethyl acetate (1:1), hexane-ethyl acetate (1:2), then ethyl acetate] gave 17 as a 
white solid (64%). mp 101-103 ºC (from ethylactetate/hexane). IR (KBr) 1728, 1708, 1433, 1285, 1130, 
1071 cm
-1
. 
1
H NMR (400 MHz, CDCl3) δ 3.82 (s, 3H), 3.83 (s, 3H), 4.27 (s, 2H), 5.04 (s, 2H), 7.19 (s, 
1H). 
13
C NMR (100 MHz, CDCl3) δ 30.1, 49.1, 51.5, 51.6, 107.8, 120.5, 121.6, 142.8, 163.6, 163.7. MS 
(EI) m/z 241 (M
+
, 30%), 209 (100), 164 (59), 151 (46), 134 (25), 123 (36). HRMS (EI-TOF) m/z 
241.0412 (M
+
, C10H11NO4S requires 241.0409). 
 
4.2.3. 2-Oxo-7-trifluoromethyl-1H,3H-pyrrolo[1,2-c]thiazole (24). A 25 mL flask with a solution of 7-
trifluoromethyl-1H,3H-pyrrolo[1,2-c]thiazole 23 (4.03 mmol) in ethyl acetate (12 mL) was charge with 
Na2WO4.H2O (0.05 M in water, 12 L, 0.6 mol), C6H5PO3H2 (0.05 M in water, 12 L, 0.6 mol), 
CH3N[(CH2)7CH3]Cl (0.05 M in methanol, 12 L, 0.6 mol) and 35% H2O2 (4.84 mmol). This mixture 
was vigorously stirred at 35-40 ºC. After 3 hours, a new load of catalyst was added and stirred overnight 
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13 
at 35-40 ºC. The reaction mixture was washed with 10 % (w/v) aqueous sodium bisulfite and the aqueous 
phase was extracted with ethyl acetate. The organic phase was and then dried over anhydrous MgSO4 and 
the solvent evaporated off. The crude product of the reaction was washed with ethyl ether giving 
compound 24 as a white solid in 90% yield. mp 101-102 ºC. IR (KBr) 1597, 1486, 1380, 1266, 1161, 
1108, 1084, 1031, 979 cm
-1
. 
1
H NMR (400 MHz, CDCl3) δ
  
4.10 (d, J = 16.4 Hz, 1H), 4.34 (dd, J = 1.0 
and 16.4 Hz, 1H), 4.87 (d, J = 11.6 Hz, 1H), 5.06 (d, J = 11.6 Hz, 1H), 6.48 (d, J = 2.8 Hz, 1H), 6.70 (d, J 
= 2.8 Hz, 1H). 
13
C NMR (100 MHz, CDCl3) δ 51.6, 69.2, 110.3 (q, J C-CF3 = 37.4 Hz), 111.9 (q, J C-C-CF3 = 
2.8 Hz), 117.4, 123.4 (q, J C-F3 = 264.4 Hz), 129.3 (q, J C-C-CF3 = 4.1 Hz). MS (EI) m/z 209 (M
+
, 54%), 161 
(100), 142 (15), 92 (14). HRMS (EI-TOF) m/z 209.0127 (M
+
, C7H6NOF3S requires 209.0122). 
 
4.3. General procedure for the synthesis of 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylates. 
To a stirred ice-cold solution of the appropriate dimethyl pyrrolo[1,2-c]thiazole-6,7-dicarboxylate 
(13.0 mmol) in dry dichloromethane (70 mL) was added portionwise 3-chloroperoxybenzoic acid (13.0 
mmol) under N2 atmosphere.  The cooling bath was removed and the reaction mixture was allowed to 
warm to room temperature.  After stirring at room temperature for 1 h, the reaction mixture was washed 
twice with 10 % (w/v) aqueous sodium bisulfite solution (2 x 100 mL) and twice with 10 % (w/v) 
aqueous sodium bicarbonate solution (2 x 100 mL).  The organic fraction was then dried over anhydrous 
sodium sulphate and the solvent evaporated off.  The crude product was purified by flash chromatography 
[hexane-ethyl acetate]. 
 
4.3.1. Dimethyl 2-oxo-3-benzyl-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (8a). 
Compound 8a was obtained as a mixture of diastereoisomers which was separated by flash 
chromatography [hexane-ethyl acetate (1:2), ethyl acetate, then ethyl acetate-methanol (9:1)]. Major 
isomer was obtained as a white solid in 76% yield; mp 113-115 ºC (from ethyl ether). IR (KBr) 1729, 
1684, 1644, 1558, 1451, 1094 cm
-1
. 
1
H NMR (300 MHz, CDCl3) δ 2.31 (s, 3H), 3.20 (dd, J = 5.2 and 14.4 
Hz, 1H, CH2Ph), 3.28 (dd, J = 4.8 and 14.4 Hz, 1H, CH2Ph), 3.36 (d, J = 17.4 Hz, 1H), 3.76 (s, 3H), 3.86 
(s, 3H), 3.99 (d, J = 14.4 Hz, 1H), 5.23 (approx. t, J = 5.2 Hz, 1H, CHBn), 6.88-6.89 (m, 2H, ArH), 7.25-
7.31 (m, 3H, ArH). 
13
C NMR (100 MHz, CDCl3) δ 11.4, 37.3, 51.4, 51.6, 51.8, 83.1, 110.1, 117.8, 128.4, 
129.2, 129.3, 131.8, 132.6, 136.6, 163.4, 164.8. MS (EI-TOF) m/z 361 (M
+
, 4%), 311 (38), 254 (37), 222 
(100), 134 (67). HRMS (EI-TOF) m/z 361.0985 (M
+
, C18H19NO5S requires 361.0984).  D
25
  = + 245 (c 1, 
CH2Cl2). Minor isomer was obtained as colourless needles in 3% yield; mp 143-144 ºC (from hexane-
ethyl acetate); IR (KBr) 1743, 1701, 1445, 1170, 1094, 1068 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 1.66 (s, 
3H), 3.06 (dd, J = 9.2 and 14.4 Hz, 1H, CH2Ph), 3.58 (dd, J = 3.6 and 14.4 Hz, 1H, CH2Ph), 3.80 (s, 3H), 
3.81 (s, 3H), 3.95 (d, J = 14.8 Hz, 1H), 4.78 (d, J = 14.8 Hz, 1H), 5.23 (dd, J = 4.0 and 9.2 Hz, 1H, 
CHBn), 7.09-7.10 (m, 2H, ArH), 7.27-7.32 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 10.8, 32.8, 
48.3, 51.6, 51.7, 71.4, 111.7, 115.7, 127.8, 128.9, 129.2, 129.9, 133.3, 134.5, 163.5, 164.7. MS (EI-TOF) 
m/z 361 (M
+
, 10%), 329 (38), 312 (65), 280 (100), 249 (73), 222 (57), 178 (59). HRMS (EI-TOF) m/z 
361.0983 (M
+
, C18H19NO5S requires 361.0984).  D
25
  = + 85 (c 1, CH2Cl2). 
 
4.3.2. Dimethyl 2-oxo-3,5-dimethyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (8b). This compound 
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14 
was prepared in the same manner described above, except that the reaction was carried at room 
temperature for 30 min. The crude product was purified by flash chromatography [hexane-ethyl acetate 
(1:1), ethyl acetate, then ethyl acetate-methanol (9:1)]. Compound 8b was obtained as a white solid in 
74% yield. mp 104-105 ºC (from ethyl ether). IR (KBr) 1733, 1705, 1306, 1098, 1058 cm
-1
. 
1
H NMR
 
(400 
MHz, CDCl3) δ 1.55 (d, J = 7.1 Hz, 3H), 2.42 (s, 3H), 3.81 (s, 3H), 3.85 (s, 3H), 4.26 (d, J = 17.4 Hz, 
1H), 4.34 (d, J = 17.4 Hz, 1H), 5.08 (q, J = 7.1 Hz, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.2, 16.3, 51.0, 
51.5, 51.6, 77.8, 110.5, 117.5, 131.5, 134.8, 163.5, 164.8. MS (EI) m/z 285 (M
+
, 14%), 237 (79), 205 
(100), 178 (39), 147 (42), 119 (40). HRMS (EI-TOF) m/z 285.0675 (M
+
, C12H15NO5S requires 285.0671). 
 
4.3.3. Dimethyl 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (18). This compound was 
prepared in the same manner described above, except that the reaction was carried at 0 ºC for 30 min. 
The product was obtained as colourless oil which crystallizes with ethyl ether to give a white solid in 45% 
yield. mp 133-135 ºC; IR (KBr) 1722, 1702, 1438, 1287, 1204, 1126, 1073 cm
-1
. 
1
H NMR
 
(400 MHz, 
CDCl3) δ 3.82 (s, 3H), 3.84 (s, 3H), 4.32 (d, J = 17.1 Hz, 1H), 4.42 (d, J = 17.1 Hz, 1H), 4.91 (d, J = 12.1 
Hz, 1H), 5.08 (d, J = 12.1 Hz, 1H), 7.28 (s, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 51.6, 51.7, 53.4, 69.6, 
111.1, 121.0, 123.0, 138.0, 163.1, 163.2. MS (EI) m/z 257 (M
+
, 33%), 225 (29), 209 (100), 194 (36), 178 
(20), 164 (22). HRMS (EI-TOF) m/z 257.0362 (M
+
, C10H11NO5S requires 257.0358). 
 
4.4. General procedures for generation and trapping of pyrrolo[1,2-c]thiazole and pyrazolo[1,5-
c]thiazole heteropentalenes. 
Method A. A solution of the appropriate 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole or 2-oxo-1H,3H-
pyrazolo[1,5-c]thiazole (1.02 mmol) and dipolarophile (1.22 mmol) in acetic anhydride (5 mL) was 
heated to reflux for time indicated in each case. After cooling to room temperature, the solvent was 
removed in vacuo and the products were isolated by crystallisation and/or flash chromatography. 
 
Method B. A 35 mL sealed tube was charged with the appropriate 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole or 
2-oxo-1H,3H-pyrazolo[1,5-c]thiazole (1.11 mmol), dipolarophile (1.33 mmol) and acetic anhydride (5 
mL). The reaction mixture was heated at 140 ºC for the time indicated in each case. After cooling to room 
temperature, the solvent was removed in vacuo and the products were isolated by crystallisation and/or 
flash chromatography. 
 
Method C. A solution of the appropriate 2-oxo-1H,3H-pyrrolo[1,2-c]thiazole or 2-oxo-1H,3H-
pyrazolo[1,5-c]thiazole (1.14 mmol) and dipolarophile (1.36 mmol) in acetic anhydride (2 mL) was 
irradiated in the microwave reactor with the temperature and time indicated in each case. After cooling to 
room temperature, the solvent was removed in vacuo and the products were isolated by crystallisation 
and/or flash chromatography. 
 
4.4.1. Dimethyl 1,3-dioxo-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (3a, exo) and (3b, endo). 
Method A (reaction time: 4 h). Trituration of the residue with methanol followed by purification by flash 
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chromatography [hexane-ethyl acetate (2:1), then (1:1)] gave, in order of elution, exo-adduct 3a (54%) 
and endo-adduct 3b (8%) both as solids.  
Method B (reaction time: 4 h).  Trituration of the residue with ethyl acetate followed by purification by 
flash chromatography [hexane-ethyl acetate (2:1), then (1:1)] gave, in order of elution, exo-adduct 3a 
(58%) and endo-adduct 3b (14%).  
Method C (temperature set to 180 ºC for 20 min). Purification by flash chromatography [hexane-ethyl 
acetate (1:1)] gave, in order of elution, exo-adduct 3a (73%) and endo-adduct 3b (10%).  
Dimethyl 1,3-dioxo-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-
7,8-dicarboxylate (3a). mp 209-211 ºC (from ethyl ether), lit. 210-211 ºC
2
, 210-212 ºC
3
. 
1
H NMR
 
(400 
MHz, CDCl3) δ 2.46 (s, 3H), 3.48 (d, J = 8.0 Hz, 1H, imide α-H), 3.51 (d, J = 8.0 Hz, 1H, imide α-H), 
3.84 (s, 3H), 3.87 (s, 3H), 5.49 (s, 1H, sulphur bridge-H), 6.03 (s, 1H, sulphur bridge-H), 7.25-7.27 (m, 
2H, ArH), 7.42-7.52 (m, 3H, ArH). 
Dimethyl 1,3-dioxo-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine 
7,8-dicarboxylate (3b). mp 244-246 ºC (from ethyl ether), lit.
2
 245-247 ºC. 
1
H NMR
 
(400 MHz, CDCl3) δ 
2.34 (s, 3H), 3.81 (s, 3H), 3.82 (s, 3H), 4.19-4.26 (m, 2H, imide α-H), 5.55 (d, J = 4.0 Hz, 1H, sulphur 
bridge-H), 6.10 (d, J = 2.4 Hz 1H, sulphur bridge-H), 6.82-6.84 (m, 2H, ArH), 7.33-7.38 (m, 3H, ArH). 
 
4.4.2. Tetramethyl 4a-methyl-4a,6a-dihydrothiazolo[2,3,4-cd]pyrrolizine-3,4,5,6-tetracarboxylate (4). 
Method A (reaction time: 4 h).  Trituration of the residue with methanol followed by recrystallization with 
the same solvent gave compound 4 as a pale yellow solid (51%).  
Method B (reaction time: 4 h).  Trituration of the residue with methanol followed by recrystallization with 
the same solvent gave compoud 4 (35%). 
Method C (temperature set to 180 ºC for 20 min). Trituration of the residue with methanol followed by 
recrystallization with the same solvent gave compound 4 (15%). 
Tetramethyl 4a-methyl-4a,6a-dihydrothiazolo[2,3,4-cd]pyrrolizine-3,4,5,6-tetracarboxylate (4). mp 238-
240 ºC lit. 238-240 ºC
2
,
 
239-241 ºC
3
. 
1
H NMR
 
(400 MHz, CDCl3) δ 1.69 (s, 3H), 3.74 (s, 3H), 3.77 (s, 
9H), 4.99 (s, 1H), 5.75 (s, 1H). 
 
4.4.3. Dimethyl 1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrazolo[1,5-a]pyrrolo[3,4-
c]pyridine-7,8-dicarboxylate (5).  
Method A (reaction time: 7 h). Trituration of the residue with methanol followed by recrystallization with 
the same solvent gave exo-adduct 5 (76%). 
Method B (reaction time: 7 h).  Trituration of the residue with methanol followed by recrystallization with 
the same solvent gave exo-adduct 5 (71%). 
Method C (temperature set to 180 ºC for 15 min). Trituration of the residue with methanol followed by 
recrystallization with the same solvent gave exo-adduct 5 (54%) which was identified by comparison with 
the specimen previously prepared. 
Dimethyl 1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrazolo[1,5-a]pyrrolo[3,4-
c]pyridine-7,8-dicarboxylate (5). White solid, mp 199-201 ºC lit.
3
 202-203 ºC. 
1
H NMR
 
(400 MHz, 
CDCl3) δ 3.53 (d, J = 6.0 Hz, 1H, imide α-H), 3.68 (dd, J = 1.2 and 6.4 Hz, 1H, imide α-H), 3.92 (s, 3H), 
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3.96 (s, 3H), 5.52 (s, 1H, sulphur bridge-H), 6.28 (s, 1H, sulphur bridge-H), 7.25-7.27 (m, 2H, ArH), 
7.45-7.52 (m, 3H, ArH). 
 
4.4.4. Tetramethyl pyrazolo[1,5-a]pyridine-2,3,5,6-tetracarboxylate (6). 
Method A (reaction time: 7 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave compound 6 (45%). 
Method B (reaction time: 7 h).  Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave compound 6 (45%). 
Method C (temperature set to 180 ºC for 15 min). Purification by flash chromatography [hexane-ethyl 
acetate (2:1), then (1:1)] gave compound 6 (53%). 
Tetramethyl pyrazolo[1,5-a]pyridine-2,3,5,6-tetracarboxylate (6). Yellow solid, mp 99-101 ºC (from 
ethyl acetate/hexane), lit.
19
 95-97 ºC. 
1
H NMR
 
(400 MHz, CDCl3) δ 3.96 (s, 3H), 3.97 (s, 3H), 3.98 (s, 
3H), 4.05 (s, 3H), 8.40 (s, 1H), 9.00 (s, 1H). 
 
4.4.5. Non-classical dimethyl 3-benzyl-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (11), 
dimethyl 1,3-dioxo-4-benzyl-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (9a, exo) and (10a, endo).  
Method A (reaction time: 4 h). Trituration of the residue with methanol followed by flash chromatography 
[hexane-ethyl acetate (3:1), (2:1), then (1:1)] gave, in order of elution, 11 (23%), endo-adduct 10a (20%) 
and exo-adduct 9a (22%). 
Method C (temperature set to 160 ºC for 20 min). Purification by flash chromatography [hexane-ethyl 
acetate (3:1), (2:1), then (1:1)] gave, in order of elution, 11 (36%), endo-adduct 10a (23%) and exo-
adduct 9a (10%). 
Non-classical dimethyl 3-benzyl-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (11). White 
solid, mp 149-150 ºC (from methanol). IR (KBr) 1702, 1581, 1546, 1445, 1408, 1383, 1229, 1177, 1090 
cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.70 (s, 3H), 3.81 (s, 3H), 3.88 (s, 3H), 4.41 (s, 2H), 6.87 (s, 1H), 
7.24-7.27 (m, 1H, ArH), 7.37-7.43 (m, 4H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 13.4, 29.3, 51.5, 52.0, 
107.6, 109.4, 119.7, 127.1, 128.0, 128.6, 129.1, 135.4, 136.2, 139.2, 163.6, 165.4. MS (EI) m/z 343 (M
+
, 
50%), 311 (98), 225 (34), 134 (100). HRMS (ESI-TOF) m/z 344.0958 ([M+1]
+
, C18H18NO4S requires 
344.0951). 
Dimethyl 1,3-dioxo-4-benzyl-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (10a). Pale yellow solid, mp 238-240 ºC (from ethyl ether). IR (KBr) 1714, 
1388, 1207, 1094 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.39 (s, 3H), 3.73 (s, 3H), 3.76 (s, 3H), 3.78 (d, J = 
13.6 Hz, 1H), 3.92 (d, J = 8.4 Hz, 1H, imide α-H), 3.98 (dd, J = 4.0 and 8.4 Hz, 1H, imide α–H), 4.38 (d, 
J = 13.6 Hz, 1H), 5.28 (d, J = 4.0 Hz, 1H, sulphur bridge-H), 6.78-6.80 (m, 2H, ArH), 7.19-7.40 (m, 8H, 
ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 10.7, 35.6, 47.6, 50.6, 50.8, 53.3, 54.4, 89.1, 106.5, 115.2, 125.6, 
127.3, 128.1, 128.2, 129.0, 129.6, 130.7, 133.4, 140.2, 161.8, 164.1, 170.4, 171.0. MS (ESI-TOF) m/z 539 
([M+Na]
+
, 100%), 413 (5), 279 (6), 227 (21). HRMS (ESI-TOF) m/z 539.1244 ([M+Na]
+
, 
C28H24N2O6SNa requires 539.1247). 
Dimethyl 1,3-dioxo-4-benzyl-6-methyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
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f]indolizine-7,8-dicarboxylate (9a). Pale yellow solid, mp 201-203 ºC (from ethyl ether). IR (KBr) 1710, 
1390, 1208, 1173, 1079 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.38 (s, 3H), 3.34 (d, J = 6.4 Hz, 1H, imide 
α-H), 3.50 (dd, J = 0.8 and 6.4 Hz, 1H, imide α–H), 3.84 (s, 3H), 3.87 (s, 3H), 4.19 (d, J = 18.0 Hz, 1H), 
4.31 (d, J = 18.0 Hz, 1H), 5.44 (bs, 1H, sulfur bridge-H), 7.22-7.32 (m, 8H, ArH), 7.42-7.51 (m, 2H, 
ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.7, 36.6, 48.6, 51.6, 51.8, 54.4, 55.4, 90.1, 107.5, 116.2, 126.6, 
128.4, 129.1, 129.3, 130.0, 130.7, 131.8, 134.4, 141.3, 162.8, 165.1, 171.4, 172.0. MS (ESI-TOF) m/z 539 
([M+1]
+
, 100%), 517 (24), 336 (6), 245 (6), 201 (35). HRMS (ESI-TOF) m/z 517.1419 ([M+1]
+
, 
C28H25N2O6S requires 517.1428). 
 
4.4.6. Non-classical dimethyl 3-benzyl-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-dicarboxylate (11), 
dimethyl 1,3-dioxo-4-benzyl-2,6-dimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (9b, exo) and (10b, endo).  
Method A (reaction time: 4 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave, in order of elution, 11 (21%), endo-adduct 10b (39%) and exo-adduct 9b (10%). 
Method B (reaction time: 4 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave, in order of elution, 11 (16%) and endo-adduct 10b (10%). 
Method C (temperature set to 160 ºC for 20 min). Purification by flash chromatography [hexane-ethyl 
acetate (2:1), then (1:1)] gave, in order of elution, 11 (16%), endo-adduct 10b (8%) and exo-adduct 9b 
(6%). 
Compound 11 was characterized by comparison with a specimen previously prepared. 
Dimethyl 1,3-dioxo-4-benzyl-2,6-dimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (10b). Yellow solid, mp 101-103 ºC (from ethyl ether). IR (KBr) 1778, 
1703, 1434, 1290, 1210, 1123, 1087 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.47 (s, 3H), 2.57 (s, 3H), 3.77-
3.86 (m, 3H, imide α-H and CH2Ph), 3.80 (s, 3H), 3.83 (s, 3H), 4.40 (d, J = 13.6 Hz, 1H, imide α–H), 
5.25 (d, J = 4.0 Hz, 1H, sulfur bridge-H), 7.36-7.45 (m, 5H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.6, 
24.5, 36.6, 48.5, 51.6, 51.8, 54.0, 55.4, 90.1, 107.6, 116.1, 128.3, 129.0, 130.0, 131.9, 134.5, 141.2, 162.8, 
165.1, 172.4, 172.9. MS (EI-TOF) m/z 454 (M
+
, 13%), 422 (100), 336 (86). HRMS (EI-TOF) m/z 
454.1198 (M
+
, C23H22N2O6S requires 454.1199). 
Dimethyl 1,3-dioxo-4-benzyl-2,6-dimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (9b). Yellow oil. IR (film) 1701, 1437, 1403, 1384, 1297, 1211, 1121, 
1083 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.35 (s, 3H), 3.05 (s, 3H), 3.19 (d, J = 6.4 Hz, 1H, imide α–H), 
3.34-3.36 (m, 1H, imide α–H), 3.82 (s, 3H), 3.86 (s, 3H), 4.14 (d, J = 18.0 Hz, 1H), 4.28 (d, J = 18.0 Hz, 
1H), 5.34 (bs, 1H, sulphur bridge-H), 7.27-7.30 (m, 5H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.6, 25.4, 
33.3, 49.2, 51.8, 51.9, 53.4, 56.9, 87.2, 106.5, 116.6, 127.5, 128.7, 128.8, 131.3, 135.3, 143.1, 163.2, 
165.3, 173.0, 173.8. MS (EI-TOF) m/z 454 (M
+
, 8%), 422 (100), 336 (86). HRMS (EI-TOF) m/z 
454.1195 (M
+
, C23H22N2O6S requires 454.1199). 
  
4.4.7. Dimethyl 1,3-dioxo-4,6-dimethyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (12a, exo) and (13a, endo). 
Method A (reaction time: 4 h). Trituration of the residue with methanol followed by purification by flash 
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chromatography [hexane-ethyl acetate (2:1), then (1:1)] gave, in order of elution exo-adduct 12a (39%) 
and endo-adduct 13a (15%). 
Method B (reaction time: 4 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave exo-adduct 12a (36%). 
Method C (temperature set to 140 ºC for 20 min). Trituration of the residue with methanol followed by 
purification by flash chromatography [hexane-ethyl acetate (2:1), then (1:1)] gave exo-adduct 12a (20%). 
Dimethyl 1,3-dioxo-4,6-dimethyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (12a). White solid, mp 223-225 ºC (from ethyl ether). IR (KBr) 1720, 
1712, 1692, 1441, 1388, 1200, 1174, 1146, 1078 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.41 (s, 3H), 2.50 
(s, 3H), 3.28 (d, J = 6.7 Hz, 1H, imide α–H), 3.56 (dd, J = 1.5 and 6.7 Hz, 1H, imide α–H), 3.84 (s, 3H), 
3.86 (s, 3H), 5.39 (d, J = 1.5 Hz, 1H, sulphur bridge-H), 7.25-7.28 (m, 2H, ArH), 7.46-7.50 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.8, 17.1, 50.5, 51.8, 51.9, 53.6, 56.6, 83.4, 106.4, 115.6, 126.4, 129.2, 
129.3, 131.1, 131.5, 142.8, 163.2, 165.4, 171.9, 173.1. MS (EI) m/z 440 (M
+
, 38%), 408 (28), 267 (100). 
HRMS (ESI-TOF) m/z 441.1102 ([M+1]
+
, C22H21N2O6S requires 441.1115). 
Dimethyl 1,3-dioxo-4,6-dimethyl-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (13a). Pale yellow solid, mp 233-235 ºC (from dichloromethane/methanol). 
IR (KBr) 1780, 1718, 1444, 1389, 1211, 1144, 1087 cm
-1
. 
1
H NMR
 
(300 MHz, CDCl3) δ 2.37 (s, 3H), 
2.50 (s, 3H), 3.80 (s, 3H), 3.81 (s, 3H), 3.95 (d, J = 8.3 Hz, 1H, imide α–H), 4.31 (dd, J = 4.2 and 8.3 Hz, 
1H, imide α–H), 5.44 (d, J = 4.2 Hz, 1H, sulphur bridge-H), 6.82-6.86 (m, 2H, ArH), 7.35-7.38 (m, 3H, 
ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.2, 18.1, 50.3, 51.6, 51.7, 56.0, 59.1, 84.0, 107.6, 115.7, 126.6, 
129.1, 129.2, 130.6, 132.0, 140.6, 162.8, 165.0, 171.2, 171.5. MS (EI) m/z 440 (M
+
, 37%), 408 (26), 267 
(100). HRMS (ESI-TOF) m/z 463.0952 ([M+Na]
+
, C22H20N2O6SNa requires 463.0934). 
 
4.4.8. Dimethyl 1,3-dioxo-2,4,6-trimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-
f]indolizine-7,8-dicarboxylate (12b, exo) and (13b, endo). 
Method A (reaction time: 4 h). Trituration of the residue with methanol followed by purification by flash 
chromatography [hexane-ethyl acetate (2:1), then (1:1)] gave, in order of elution, exo-adduct 12b (19%) 
and endo-adduct 13b (23%). 
Method B (reaction time: 4 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave, in order of elution, exo-adduct 12b (20%) and endo-adduct 13b (19%). 
Dimethyl 1,3-dioxo-2,4,6-trimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (12b). Pale yellow solid, mp 186-188 ºC (from ethyl acetate/hexane). IR (KBr) 1781, 1711, 
1436, 1299, 1203, 1142, 1083 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.36 (s, 3H), 2.47 (s, 3H), 3.03 (s, 3H), 
3.14 (d, J = 6.4 Hz, 1H, imide α–H), 3.40 (approx. d, J = 6.0 Hz, 1H, imide α–H), 3.82 (s, 3H), 3.84 (s, 
3H), 5.28 (bs, 1H, sulphur bridge-H). 
13
C NMR
 
(100 MHz, CDCl3) δ 11.7, 17.1, 25.3, 50.0, 51.7, 51.8, 
53.7, 56.7, 83.0, 106.2, 115.4, 131.1, 142.9, 163.2, 165.3, 172.9, 174.0. MS (EI) m/z 378 (M
+
, 34%), 346 
(32), 267 (100), 177 (20), 149 (18). HRMS (EI-TOF) m/z 378.0888 (M
+
, C17H18N2O6S requires 
378.0886). 
Dimethyl 1,3-dioxo-2,4,6-trimethyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (13b). Yellow oil. IR (film) 1702, 1434, 1402, 1290, 1211, 1090 cm
-1
. 
1
H NMR
 
(400 MHz, 
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CDCl3) δ 2.31 (s, 3H), 2.39 (s, 3H), 2.46 (s, 3H), 3.66 (d, J = 8.0 Hz, 1H, imide α–H), 3.71 (s, 3H), 3.75 
(s, 3H), 4.01-4.06 (m, 1H, imide α–H), 5.28 (d, J = 4.0 Hz, 1H, sulfur bridge-H). 13C NMR (100 MHz, 
CDCl3) δ 11.2, 18.1, 24.5, 50.2, 51.6, 51.7, 56.0, 58.7, 84.0, 107.6, 115.6, 132.1, 140.5, 162.9, 165.1, 
172.2, 172.4. MS (EI) m/z 378 (M
+
, 35%), 346 (33), 267 (100), 177 (22), 149 (18). HRMS (EI-TOF) m/z 
378.0886 (M
+
, C17H18N2O6S requires 378.0886). 
 
4.4.9.  Dimethyl 1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (19a, exo) and (20a, endo) and dimethyl 5,7-dioxo-6-phenyl-4b,5,6,7,7a,7b-hexahydro-2H-
pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine-3,4-dicarboxylate (21a, endo). 
Method A (reaction time: 4 h). Trituration of the residue with methanol followed by purification by flash 
chromatography [hexane-ethyl acetate (2:1), (1:1), then (1:2)] gave, in order of elution, exo-adduct 19a 
(33%) and endo-adduct 21a (18%). 
Method B (reaction time: 4 h). Trituration of the residue with methanol followed by purification by flash 
chromatography [hexane-ethyl acetate (2:1), (1:1), then (1:2)] gave, in order of elution, exo-adduct 19a 
(28%) and a mixture of endo-adduct 20a (7%) and endo-adduct 21a (12%). The endo-adduct 21a was 
isolated from the mixture by selective crystallization with ethyl acetate. 
Method C (temperature set to 180 ºC for 20 min). Trituration of the residue with methanol gave exo-
adduct 19a (55%). Purification of the residue by flash chromatography [hexane-ethyl acetate (1:1)] gave 
endo-adduct 20a (13%). 
Dimethyl 1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (19a). White solid, mp 207-209 ºC (from ethyl ether). IR (KBr) 1737, 1720, 1382, 1284, 
1187, 1070 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 3.52 (dd, J = 0.8 and 6.8 Hz, 1H, imide α-H), 3.56 (dd, J 
= 1.2 and 6.8 Hz, 1H, imide α–H), 3.83 (s, 3H), 3.90 (s, 3H), 5.55 (s, 1H, sulphur bridge-H), 6.01 (s, 1H, 
sulfur bridge-H), 7.25-7.26 (m, 2H, ArH), 7.36 (s, 1H), 7.44-7.52 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, 
CDCl3) δ 51.0, 51.8, 52.0, 52.2, 53.5, 69.6, 108.3, 118.0, 121.6, 126.4, 129.3, 129.4, 131.4, 143.1, 162.7, 
163.4, 172.2, 172.9. MS (EI) m/z 412 (M
+
) (7), 239 (100), 202 (22). HRMS (EI-TOF) m/z 412.0724 (M
+
, 
C20H16N2O6S requires 412.0729). 
Dimethyl 5,7-dioxo-6-phenyl-4b,5,6,7,7a,7b-hexahydro-2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-
cd]pyrrolizine-3,4-dicarboxylate (21a). White solid, mp 248-250 ºC. IR (KBr) 1719, 1386, 1301, 1203, 
1106 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 3.81 (s, 3H), 3.86 (s, 3H), 4.28 (d, J = 13.6 Hz, 1H, H-2), 4.33 
(approx. t, J = 7.6 Hz, 1H, H-7a), 4.78 (d, J = 13.6 Hz, 1H, H-2), 4.89 (d, J = 6.8 Hz, 1H, H-4b), 6.08 (d, 
J = 7.6 Hz, 1H, H-7b), 7.19-7.21 (m, 2H, ArH), 7.36-7.46 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 
37.5, 50.8, 51.7, 52.0, 53.2, 60.3, 115.5, 115.7, 126.3, 129.1, 129.2, 131.0, 131.2, 138.6, 162.7, 163.0, 
169.9, 170.6. MS (EI) m/z 412 (M
+
, 42%), 380 (100), 261 (26), 233 (79), 147 (42). HRMS (EI-TOF) m/z 
412.0730 (M
+
, C20H16N2O6S requires 412.0729). 
Dimethyl 1,3-dioxo-2-phenyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (20a). Yellow oil. IR (KBr) 1716, 1499, 1384, 1290, 1186, 1105, 1065 cm
-1
. 
1
H NMR
 
(400 
MHz, CDCl3) δ 3.78 (s, 3H), 3.85 (s, 3H), 4.22 (dd, J = 2.8 and 8.4 Hz, 1H, imide α-H), 4.27 (dd, J = 4.0 
and 8.4 Hz, 1H, imide α–H), 5.60 (d, J = 3.6 Hz, 1H, sulphur bridge-H), 6.10 (d, J = 2.4 Hz, 1H, sulphur 
bridge-H), 6.81-6.83 (m, 2H, ArH), 7.27 (s, 1H), 7.34-7.36 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
20 
51.7, 51.8, 52.0, 53.6, 56.2, 69.5, 108.9, 118.2, 122.4, 126.4, 129.1, 129.2, 130.5, 140.9, 162.3, 163.2, 
171.0, 171.2. MS (EI) m/z 412 (M
+
, 4%), 378 (16), 347 (18), 239 (100), 208 (11), 202 (10). HRMS (EI-
TOF) m/z 412.0727 (M
+
, C20H16N2O6S requires 412.0729). 
 
4.4.10. Dimethyl 1,3-dioxo-2-methyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-
7,8-dicarboxylate (19b, exo) and (20b, endo) and dimethyl 5,7-dioxo-6-methyl-4b,5,6,7,7a,7b-hexahydro-
2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine-3,4-dicarboxylate (21b, endo). 
Method A (reaction time: 4 h). Trituration of the residue with ethyl acetate gave exo-adduct 19b (20%). 
Purification of the residue by flash chromatography [hexane-ethyl acetate (1:1), (1:2), then ethyl acetate] 
gave a mixture of endo-adduct 20b (9%) and endo-adduct 21b (27%). Compound 21b was isolated from 
the mixture by selective crystallization with ethyl acetate. 
Method B (reaction time: 4 h). Trituration of the residue with ethyl acetate gave exo-adduct 19b (19%). 
Purification of the residue by flash chromatography [hexane-ethyl acetate (1:1), (1:2), then (1:3)] gave a 
mixture of endo-adduct 20b (2%) and endo-adduct 21b (16%). 
Method C (temperature set to 180 ºC for 20 min). Trituration of the residue with ethyl acetate gave exo-
adduct 19b (19%). Purification of the residue by flash chromatography [hexane-ethyl acetate (1:1), (1:2), 
then (1:3)] gave a mixture of endo-adduct 20b (8%) and endo-adduct 21b (26%). 
Dimethyl 1,3-dioxo-2-methyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (19b). White solid, mp 256-258 ºC (from methanol). IR (KBr) 1736, 1692, 1439, 1383, 
1288, 1181, 1061 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 3.03 (s, 3H), 3.36 (d, J = 6.8 Hz, 1H, imide α-H), 
3.40 (d, J = 6.8 Hz, 1H, imide α–H), 3.82 (s, 3H), 3.89 (s, 3H), 5.43 (s, 1H, sulphur bridge-H), 5.95 (s, 
1H, sulphur bridge-H), 7.32 (s, 1H). 
13
C NMR (100 MHz, CDCl3) δ 25.4, 51.1, 51.7, 51.8, 52.0, 53.6, 
69.2, 108.1, 118.0, 121.5, 143.2, 162.7, 163.4, 173.0, 173.8. MS (EI) m/z 350 (M
+
, 54%), 318 (100), 291 
(26), 260 (20), 233 (39), 147 (21). HRMS (EI-TOF) m/z 350.0579 (M
+
, C15H14N2O6S requires 350.0573). 
Dimethyl 1,3-dioxo-2-methyl-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (20b). Yellow oil. IR (film) 1781, 1705, 1435, 1383, 1290, 1208, 1104 cm
-1
. 
1
H NMR
 
(400 
MHz, CDCl3) δ 2.54 (s, 3H), 3.78 (s, 3H), 3.86 (s, 3H), 4.04 (dd, J = 3.2 and 8.0 Hz, 1H, imide α-H), 4.10 
(dd, J = 4.0 and 8.0 Hz, 1H, imide α–H), 5.49 (d, J = 4.0 Hz, 1H, sulphur bridge-H), 6.03 (d, J = 3.2 Hz, 
1H, sulphur bridge-H), 7.21 (s, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 24.6, 51.6, 51.8, 51.9, 53.6, 55.9, 
69.4, 108.8, 117.9, 122.5, 140.8, 162.4, 163.2, 171.9, 172.0. MS (EI) m/z 350 (M
+
, 57%), 318 (100), 291 
(29), 260 (20), 233 (40), 147 (21). HRMS (EI-TOF) m/z 350.0571 (M
+
, C15H14N2O6S requires 350.0573). 
Dimethyl 5,7-dioxo-6-methyl-4b,5,6,7,7a,7b-hexahydro-2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-
cd]pyrrolizine-3,4-dicarboxylate (21b). White solid, mp 222-223 ºC. IR (KBr) 1777, 1731, 1697, 1434, 
1300, 1119, 1103 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.96 (s, 3H), 3.80 (s, 3H), 3.89 (s, 3H), 4.16 
(approx. t, J = 7.6 Hz, 1H, H-7a), 4.24 (d, J = 14.0 Hz, 1H, H-2), 4.73-4.74 (m, 2H, H-2 and H-4b), 6.00 
(d, J = 7.6 Hz, 1H, H-7b). 
13
C NMR
 
(100 MHz, CDCl3) δ 25.7, 37.4, 50.9, 51.7, 52.0, 53.2, 60.0, 115.3, 
115.5, 131.4, 138.2, 162.8, 163.0, 171.0, 171.7. MS (EI) m/z 350 (M
+
, 15%), 319 (9), 239 (100), 208 (14). 
HRMS (EI-TOF) m/z 350.0574 (M
+
, C15H14N2O6S requires 350.0573. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
4.4.11. 5,7(4bH,6H)-Dioxo-6-phenyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-
pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine (26a, exo) and (27a, endo). 
Method A (reaction time: 7 h). Purification by flash chromatography [hexane-ethyl acetate (3:1)] gave, in 
order of elution, exo-adduct 26a (11%) and endo-adduct 27a (30%). 
Method B (reaction time: 7 h). Purification by flash chromatography [hexane-ethyl acetate (3:1), then 
(2:1)] gave, in order of elution, exo-adduct 26a (10%) and endo-adduct 27a (26%). 
5,7(4bH,6H)-Dioxo-6-phenyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-
cd]pyrrolizine (26a). Colourless needles, mp 191-193 ºC (from ethyl ether). IR (KBr) 1716, 1392, 1241, 
1174, 1109, 1069 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 4.08 (d, J = 13.6 Hz, 1H, H-2), 4.35 (dd, J = 5.6 
and 8.4 Hz, 1H, H-7a), 4.65 (d, J = 8.8 Hz, 1H, H-4b), 4.76 (d, J = 13.6 Hz, 1H, H-2), 5.95 (d, J = 5.6 Hz, 
1H, H-7b), 6.25 (s, 1H), 7.30-7.32 (m, 2H, ArH), 7.43-7.53 (m, 3H, ArH). 
13
C NMR
 
(100 MHz, CDCl3) δ 
36.0, 49.6, 57.8, 61.9, 107.9 (q, J C-C-CF3 = 3.0 Hz), 115.5 (q, J C-CF3 = 37.4 Hz), 122.7 (q, J C-F3 = 265 Hz), 
126.4, 129.2, 129.4, 130.7, 131.2, 134.3 (q, J C-C-CF3 = 4.7 Hz), 171.4, 172.3. MS (ESI-TOF) m/z 365 
([M+1]
+
, 100%). HRMS (ESI-TOF) m/z 365.0563 ([M+1]
+
, C17H12N2O2F3S requires 365.0566). 
5,7(4bH,6H)-Dioxo-6-phenyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-
cd]pyrrolizine (27a). White solid, mp 232-233 ºC (from ethyl acetate-hexane). IR (KBr) 1722, 1492, 
1376, 1239, 1186, 1101, 1049 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 4.00 (d, J = 13.6 Hz, 1H, H-2), 4.28 
(approx. t, J = 7.2 Hz, 1H, H-7a), 4.72 (d, J = 6.8 Hz, 1H, H-4b), 4.77 (d, J = 13.6 Hz, 1H, H-2), 6.09 (d, 
J = 7.6 Hz, 1H, H-7b), 6.17 (s, 1H), 7.21-7.23 (m, 2H, ArH), 7.34-7.48 (m, 3H, ArH). 
13
C NMR
 
(100 
MHz, DMSO-d6) δ 35.2, 50.4, 54.1, 59.5, 103.0 (q, J C-C-CF3 = 2.7 Hz), 112.4 (q, J C-CF3 = 36.8 Hz), 123.1 
(q, J C-F3 = 266 Hz), 126.6, 128.6, 129.0, 131.7, 133.2 (q, J C-C-CF3 = 4.9 Hz), 172.5, 172.9. MS (EI) m/z 
364 (M
+
, 100%), 217 (35), 188 (73), 177 (12). HRMS (ESI-TOF) m/z 365.0563 ([M+1]
+
, C17H12N2O2F3S 
requires 365.0566). 
 
4.4.12. 5,7(4bH,6H)-Dioxo-6-methyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-
pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine (27b, endo). 
Method A (reaction time: 7 h). Purification by flash chromatography [hexane-ethyl acetate (2:1)] gave 
endo-adduct 27b (50%).  
Method B (reaction time: 7 h). Purification by flash chromatography [hexane-ethyl acetate (2:1), then 
(1:1)] gave endo-adduct 27b (63%). 
5,7(4bH,6H)-Dioxo-6-methyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-pyrrolo[3',4':5,6]thiazolo[2,3,4-
cd]pyrrolizine (27b, endo). White solid, mp 189-191 ºC (from ethyl ether). IR (KBr) 1711, 1431, 1376, 
1283, 1246, 1226, 1167, 1090 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 2.99 (s, 3H), 3.97 (d, J = 13.3 Hz, 1H, 
H-2), 4.13 (approx. t, J = 7.2 Hz, 1H, H-7a), 4.58 (d, J = 6.7 Hz, 1H, H-4b), 4.74 (d, J = 13.3 Hz, 1H, H-
2), 6.02 (d, J = 7.5 Hz, 1H, H-7b), 6.09 (s, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 25.6, 35.9, 50.0, 54.0, 
59.6, 105.1 (q, J C-C-CF3 = 3.2 Hz), 115.2 (q, J C-CF3 = 37.5 Hz), 122.7 (q, J C-F3 = 265 Hz), 130.2, 132.2 (q, 
J C-C-CF3 = 4.7 Hz), 172.4, 172.9. MS (EI) m/z 302 (M
+
, 100%), 283 (11), 217 (44), 197 (14), 188 (19), 
172 (11), 148 (11). HRMS (EI-TOF) m/z 302.0335 (M
+
, C12H9N2O2F3S requires 302.0337). 
 
4.5. General procedure for the synthesis of dimethyl 1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-
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f]indolizine-7,8-dicarboxylates.  
 
Method A. A solution of sodium (11 mg, 0.46 mmol) dissolved in anhydrous methanol (2 mL) was added 
slowly to a solution of the appropriate dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-hexahydro-1H-
pyrrolo[3,4-f]indolizine-7,8-dicarboxylate (0.23 mmol) in anhydrous dichloromethane (5 mL). After 
stirring at room temperature for 1.5 h, the reaction was quenched with saturated aqueous ammonium 
chloride solution (5 mL). The organic phase was separated, dried over anhydrous sodium sulfate and the 
solvent evaporated off.  The crude product was purified by flash chromatography [hexane-ethyl acetate]. 
Method B. A solution of potassium tert-butoxide  (78 mg, 0.66 mmol) in anhydrous tert-butanol   (2 mL) 
was added slowly to a solution of the appropriate dimethyl 1,3-dioxo-4,9-epithio-2,3,3a,4,9,9a-
hexahydro-1H-pyrrolo[3,4-f]indolizine-7,8-dicarboxylate (0.33 mmol) in anhydrous dichloromethane (8 
mL). After stirring at room temperature for 0.5 h, the reaction was quenched with saturated aqueous 
ammonium chloride solution (5 mL). The organic phase was separated, dried over anhydrous sodium 
sulfate and the solvent evaporated off.  The crude product was purified crystallization or flash 
chromatography [hexane-ethyl acetate]. 
 
4.5.1. Dimethyl 4-benzyl-6-methyl-1,3-dioxo-2-phenyl-2,3-dihydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (14a). This compound was prepared by method A and was obtained as a yellow solid 
(38%), mp 235-237 ºC (from ethyl ether). IR (KBr) 1768, 1713, 1686, 1452, 1398, 1371, 1259, 1164, 
1068 cm
-1
. 
1
H NMR
 
(300 MHz, CDCl3) δ 2.69 (s, 3H), 3.93 (s, 3H), 3.96 (s, 3H), 5.29 (bs, 2H), 6.96-6.99 
(m, 2H, ArH), 7.25-7.30 (m, 2H, ArH), 7.40-7.50 (m, 6H, ArH), 8.80 (s, 1H). 
13
C NMR
 
(100 MHz, 
CDCl3) δ 14.5, 32.7, 52.1, 52.8, 109.5, 115.3, 116.9, 122.4, 125.8, 126.6, 127.1, 128.4, 128.8, 129.1, 
129.4, 131.6, 136.1 137.1, 140.7, 163.1, 164.6, 166.0, 166.1. MS (ESI-TOF) m/z 505 ([M+Na]
+
, 63%), 
483 [M+1]
+
 (49), 319 (15), 201 (100). HRMS (ESI-TOF) m/z 483.1539 ([M+1]
+
, C28H23N2O6 requires 
483.1551). 
 
4.5.2. Dimethyl 4,6-dimethyl-1,3-dioxo-2-phenyl-2,3-dihydro-1H-pyrrolo[3,4-f]indolizine-7,8-
dicarboxylate (14b). This compound was prepared by method B, except that tert-butanol was replaced by 
methanol as solvent.  Recrystallization with ethyl acetate/hexane gave 14b as an orange solid (87%), mp 
233-235 ºC. IR (KBr) 1763, 1704, 1457, 1397, 1388, 1236, 1094 cm
-1
. 
1
H NMR
 
(400 MHz, CDCl3) δ 
2.92 (s, 3H), 3.38 (s, 3H), 3.94 (s, 3H), 3.97 (s, 3H), 7.42-7.44 (m, 3H, ArH), 7.50-7.54 (m, 2H, ArH), 
8.63 (s, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 15.4, 15.9, 52.0, 52.8, 108.9, 113.8, 116.1, 122.9, 125.6, 
126.7, 128.4, 128.9, 129.1, 131.7, 135.7, 140.6, 163.0, 164.6, 166.1, 166.5. MS (EI) m/z 406 (M
+
, 44%), 
374 (34), 288 (100). HRMS (ESI-TOF) m/z 407.1238 ([M+1]
+
, C22H19N2O6 requires 407.1238. 
 
4.5.3. Dimethyl 2,4,6-trimethyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-f]indolizine-7,8-dicarboxylate 
(14c). This compound was prepared by method B, except that tert-butanol was replaced by 
tetrahydrofuran as solvent. Purification by flash chromatography gave 14c as a yellow solid (50%), mp 
210-212 ºC (from ethyl ether). IR (KBr) 1760, 1733, 1706, 1429, 1392, 1291, 1169 cm
-1
. 
1
H NMR
 
(400 
MHz, CDCl3) δ 2.89 (s, 3H), 3.19 (s, 3H), 3.32 (s, 3H), 3.92 (s, 3H), 3.95 (s, 3H), 8.49 (s, 1H). 
13
C NMR
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
23 
(100 MHz, CDCl3) δ 15.4, 15.8, 24.4, 51.9, 52.8, 108.7, 114.2, 115.4, 123.3, 125.4, 128.8, 135.6, 139.7, 
163.1, 165.7, 166.1, 167.5. MS (EI-TOF) m/z 344 (M
+
, 15%), 312 (33), 254 (15), 226 (100). HRMS (EI-
TOF) m/z 344.1005 (M
+
, C17H16N2O6 requires 344.1008). 
 
4.5.4. Dimethyl 1,3-dioxo-2-phenyl-2,3-dihydro-1H-pyrrolo[3,4-f]indolizine-7,8-dicarboxylate (22a). 
This compound was prepared by method B. Purification by flash chromatography gave compound 22a as 
a pale yellow solid (35%), mp 217-219 ºC (from ethyl ether). IR (KBr) 1770, 1721, 1711, 1385, 1240, 
1119. 
1
H NMR
 
(400 MHz, CDCl3) δ 3.96 (s, 3H), 4.00 (s, 3H), 7.43-7.46 (m, 3H), 7.52-7.56 (m, 2H), 
7.94 (s, 1H), 8.61 (s, 1H), 8.72 (s, 1H). MS (EI) m/z 378 (M
+
, 82%), 347 (100), 317 (25), 168 (15). 
HRMS (ESI-TOF) m/z 407.1238 ([M+1]
+
, C22H19N2O6 requires 407.1238). 
 
4.5.5. Dimethyl 2-methyl-1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-f]indolizine-7,8-dicarboxylate (22b). 
This compound was prepared by method B. Purification by flash chromatography gave compound 22b as 
a white solid (38%), mp 220-222 ºC (from ethyl ether). IR (KBr) 1766, 1736, 1708, 1431, 1210 cm
-1
. 
1
H 
NMR
 
(400 MHz, CDCl3) δ 3.22 (s, 3H), 3.94 (s, 3H), 3.97 (s, 3H), 7.88 (s, 1H), 8.49 (s, 1H), 8.60 (s, 1H). 
13
C NMR
 
(100 MHz, CDCl3) δ 24.6, 52.1, 52.6, 110.5, 117.6, 117.9, 121.2, 123.4, 123.9, 124.3, 134.8, 
163.0, 163.6, 165.6, 165.8. MS (EI) m/z 316 (M
+
, 60%), 298 (44), 285 (95), 255 (43), 240 (23), 212 
(100). HRMS (EI) m/z 316.0693 (M
+
, C15H12N2O6 requires 316.0695). 
 
4.6. Crystal-structure determination of 11 and 27a. 
Crystals of compounds 11 and 27a were selected, covered with polyfluoroether oil, and mounted on a 
nylon loop. Crystallographic data for both compounds were collected at the IST using graphite 
monochromated Mo-Kα radiation (λ=0.71073Å) on a Bruker AXS-KAPPA APEX II diffractometer 
equipped with an Oxford Cryosystem open-flow nitrogen cryostat, at 150 K. Cell parameters were 
retrieved using Bruker SMART software and refined using Bruker SAINT on all observed reflections. 
Absorption corrections were applied using SADABS.
21
 Structure solution and refinement were performed 
using direct methods with the program SIR2004
22
 included in the package of programs WINGX-Version 
1.80.05
23
 and SHELXL.
24
 All hydrogen atoms were inserted in idealized positions and allowed to refine 
riding on the parent carbon atom. Figures of the molecular structures were generated using ORTEP-III.
25 
 
4.6.1. Crystallographic data for non-classical 3-benzyl-5-methyl-1H,3H-pyrrolo[1,2-c]thiazole-6,7-
dicarboxylate (11): C18H17NO5S, M = 359.39, monoclinic, Cc with unit cell, a = 11.8618(19) Å, b = 
21.454(3) Å, c = 7.3253(12) Å, α = 90°, β = 120.633(7)°, γ = 90°, V = 1604.0(4) Å3. It contains four 
molecules/unit cell. ρcalcd. = 1.488 g cm-3, Z = 4, μ = 0.232 mm-1. R [I>2σ(I)] = 0.0806 and Rw = 0.2126 
for 2171 independent reflections. 
 
4.6.2 Crystallographic data for 5,7(4bH,6H)-dioxo-6-phenyl-3-(trifluoromethyl)-7a,7b-dihydro-2H-
pyrrolo[3',4':5,6]thiazolo[2,3,4-cd]pyrrolizine (27a): C17H11F3N2O2S, M = 364.34, triclinic, P-1 with unit 
cell, a = 8.9513(5) Å, b = 9.2025(5) Å, c = 9.8159(6) Å, α = 79.646(4)°, β = 76.155(3)°, γ = 71.164(4)°, V 
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24 
= 738.41(7) Å
3
. It contains two molecules/unit cell. ρcalcd. = 1.639 g cm-3, Z = 2, μ = 0.269 mm-1. R 
[I>2σ(I)] = 0.0300 and Rw = 0.0729 for 2652 independent reflections. 
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